<span id="midArticle_start"/> (Reuters) - Aduro Biotech Inc's initialpublic offering has been priced at $17 per share, an underwritersaid, valuing the cancer immunotherapy drug developer at about$1 billion.
<span id="midArticle_0"/>The upsized offering, which was priced on par with thecompany's expectation, raised about $119 million.
<span id="midArticle_1"/>Aduro, which counts Johnson & Johnson and NovartisAG among its investors, is selling all the 7 millionshares in the offering.
<span id="midArticle_2"/>The company had previously planned to sell 5 million sharesand expected the offering to be priced at $14-$16 per share.
<span id="midArticle_3"/>Shares of Aduro are expected to start trading on Wednesdayon the Nasdaq under the symbol "ADRO."
<span id="midArticle_4"/>BofA Merrill Lynch and Leerink Partners are the mainunderwriters for the offering. (Reporting by Avik Das in Bengaluru; Editing by SaumyadebChakrabarty)
<span id="midArticle_5"/>
<span id="midArticle_0"/>The upsized offering, which was priced on par with thecompany's expectation, raised about $119 million.
<span id="midArticle_1"/>Aduro, which counts Johnson & Johnson and NovartisAG among its investors, is selling all the 7 millionshares in the offering.
<span id="midArticle_2"/>The company had previously planned to sell 5 million sharesand expected the offering to be priced at $14-$16 per share.
<span id="midArticle_3"/>Shares of Aduro are expected to start trading on Wednesdayon the Nasdaq under the symbol "ADRO."
<span id="midArticle_4"/>BofA Merrill Lynch and Leerink Partners are the mainunderwriters for the offering. (Reporting by Avik Das in Bengaluru; Editing by SaumyadebChakrabarty)
<span id="midArticle_5"/>
via Smart Health Shop Forum http://ift.tt/1NFb0y3
No comments:
Post a Comment